MNZM

Vaccitech to Host KOL Webinar on Seeking a Functional Cure for Chronic Hepatitis B on September 20, 2023

Retrieved on: 
Wednesday, September 13, 2023
Auckland City Hospital, KOL, MNZM, FRCP, University, MBBS, University of Auckland, Q&A, Old Road Campus, Cancer, Nuffield Department of Population Health, Doctor of Philosophy, Autoimmunity, Small RNA, Medical research, Hepatology, Patient, Immune system, Safety, Vaccitech, HBV, Nivolumab, University of Oxford, Disease, MVA, Vaccine, FRACP, Bachelor of Medicine, Bachelor of Surgery, Hepatitis, Fellow of the Academy of Medical Sciences, MD

Details are as follows:

Key Points: 
  • Details are as follows:
    To register for the event, click here .
  • The Vaccitech management team will provide a clinical overview of VTP-300, the first antigen-specific immunotherapy that has been shown to induce sustained reductions in Hepatitis B surface antigen, a marker of the disease.
  • Vaccitech is studying VTP-300, including in combination with siRNA and low-dose anti-PD-1 antibodies, as part of the search for a regimen that could lead to a potential functional cure for HBV.
  • A live Q&A session will follow the formal presentations.

Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the International Liver Congress™ 2022

Retrieved on: 
Wednesday, June 8, 2022
University, Genome, Company, ATTR, CRISPR, Therapy, Serum, Review, Tissue, Cancer, U.S. Securities and Exchange Commission, Degenerative disease, Cardiomyopathy, Investor, Part, Human, European Association for the Study of the Liver, Trial of the century, Intellia Therapeutics, NTLA, Association, Population, Amyloidosis, Heart, Cas9, Auckland City Hospital, Nerve Damage, Polyneuropathy, Transthyretin, Webcast, Liver, Security (finance), Patient, Nobel Prize, Private Securities Litigation Reform Act, Regeneron Pharmaceuticals, Form 10-K, Annual report, MNZM, Heart failure, GLOBE, TTR, Amyloid, Risk, Coronavirus, NASDAQ, Clinical trial, Protein, Safety, Pharmaceutical industry, Vaccine, Bachelor of Medicine, Bachelor of Surgery, FRACP, MD, Medicine

The presentation will include new data from the ongoing Phase 1 study evaluating NTLA-2001 in people living with hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN).

Key Points: 
  • The presentation will include new data from the ongoing Phase 1 study evaluating NTLA-2001 in people living with hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN).
  • Data supporting the fixed dose selection for Part 2, the single-dose expansion cohort of the polyneuropathy arm, will also be presented.
  • There are an estimated 50,000 people worldwide living with ATTRv amyloidosis and between 200,000 and 500,000 people with ATTRwt amyloidosis.
  • Intellia Therapeutics, a leading clinical-stage genome editing company, is developing novel, potentially curative therapeutics leveraging CRISPR-based technologies.

USANA Signs Deal with Basketball New Zealand

Retrieved on: 
Tuesday, May 31, 2022
NSF, NSF International, WADA, Internationally Certified Chiropractic Sports Practitioner, Birmingham, Senior National Hockey Tournament 2019, Crelan, New Zealand women's national basketball team, Multimedia, USNA, View, Health, World Anti-Doping Agency, FIBA Asia Cup, Industry, New Zealand men's national basketball team, SALT, Partnership, World cup, Basketball, Board, Organization, Board of directors, USANA, FIBA Asia, Athlete, MNZM, Fern, NYSE, Sport, Dietary supplement, Online shopping

SALT LAKE CITY, May 31, 2022 /PRNewswire/ -- For 30 years USANA, the Cellular Nutrition Company, has been a leader in its industry. With more professional and Olympic athletes trusting USANA with their nutritional needs than any other nutritional supplement in the world, its impressive and diverse roster of athletic partners continues to soar. USANA is now the official nutritional supplement supplier of Basketball New Zealand (BBNZ), providing NSF-certified products to the Tall Blacks, Sky Sport Tall Ferns, and respective 3x3 team athletes.

Key Points: 
  • USANA is now the official nutritional supplement supplier of Basketball New Zealand (BBNZ), providing NSF-certified products to the Tall Blacks, Sky Sport Tall Ferns, and respective 3x3 team athletes.
  • "We look forward to cheering them on as they represent New Zealand in upcoming competitions and beyond."
  • "We are excited to partner with USANA for our Senior National teams," says MNZM Chief Executive of Basketball New Zealand Dillon Boucher.
  • Basketball New Zealand (BBNZ) is the national body for the sport of basketball in New Zealand.

Intellia Therapeutics Announces Two Upcoming Investor Events in February 2022

Retrieved on: 
Thursday, February 17, 2022
NASDAQ, Patient, Intellia Therapeutics, Cancer, Tissue, Cas9, Regeneron Pharmaceuticals, Polyneuropathy, University, Therapy, Nobel Prize, CRISPR, MNZM, Liver, NTLA, TTR, Amyloidosis, Auckland City Hospital, Degenerative disease, Investor, GLOBE, ATTR, Weapon, Pharmaceutical industry, Medicine, Bachelor of Medicine, Bachelor of Surgery, FRACP, MD

ET

Key Points: 
  • ET
    CAMBRIDGE, Mass., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics leveraging CRISPR-based technologies, today announced that it will be hosting two virtual investor events in February.
  • All participants should ask to be connected to the Intellia Therapeutics conference call.
  • Intellia leads development and commercialization of NTLA-2001 as part of a multi-target discovery, development and commercialization collaboration with Regeneron.
  • Intellia Therapeutics, a leading clinical-stage genome editing company, is developing novel, potentially curative therapeutics leveraging CRISPR-based technologies.

Assembly Biosciences Abstracts Selected for Presentation at the Upcoming AASLD The Liver Meeting®

Retrieved on: 
Monday, November 1, 2021
Safety, Assembly, MD, AASLD, HBeAg, Securities Act of 1933, SAN, Association, Institute of Liver and Biliary Sciences, ET, Patient, Hepatitis B virus, Sumathi Best Television Current Reporting Award, VBR, U.S. Securities and Exchange Commission, SEC, American Association for the Study of Liver Diseases, Annual report, MNZM, COVID-19, Program, Pharmacokinetics, Liver, American Association, Therapy, C1-inhibitor, GLOBE, Securities Exchange Act of 1934, HBV, DNA, Pharmaceutical industry

The presentations include updates from the clinical studies of vebicorvir (VBR) and ABI-H3733, as well as the newly selected preclinical core inhibitor candidate, ABI-4334.

Key Points: 
  • The presentations include updates from the clinical studies of vebicorvir (VBR) and ABI-H3733, as well as the newly selected preclinical core inhibitor candidate, ABI-4334.
  • AASLD will be hosted virtually November 12-15, 2021.
  • The Liver Meeting offers a valuable opportunity to further advance our understanding of HBV and liver disease, while gaining access to the latest cutting-edge research from the worlds leading liver disease experts, saidJohn McHutchison, AO, MD, chief executive officer and president of Assembly Bio.
  • Except as required by law, Assembly Bio assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.